Walsh, Garry Michael

English

PubMed

Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil&amp;trade;) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.Keywords: IL-5, asthma, eosinophi

Walsh GM

Directory of Open Access Journals

Biologics Targets and Therapy

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Aberdeen University Research

A striking local esophageal cytokine expression profile in eosinophilic esophagitis.

Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients. Clin Otolaryngol.

Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci.

Antagonism of eosinophil accumulation in asthma. Recent Pat Inflamm Allergy Drug Discov.

Basic pathogenesis of eosinophilic esophagitis.

Biology of interleukin-5 and its relevance to allergic disease.

Biology of the eosinophil. Adv Immunol.

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge.

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 downmodulates its receptor via a proteinase-mediated process.

Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity.

Effect of SCH55700, a humanized anti-human interleukin-5 antibody in severe persistent asthma: a pilot study.

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis.

Eosinophil trafficking in allergy and asthma.

Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Eosinophilic esophagitis: management and pharmacotherapy. Expert Opin Pharmacother.

Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Eosinophilic inflammation in asthma.

Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.

et al; for International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

et al; for Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Inhibition of interleukin-5 for the treatment of eosinophilic diseases.

Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Mepolizumab for prednisonedependent asthma with sputum eosinophilia.

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy.

Monoclonal antibodies and other biologic agents in the treatment of asthma.

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

Novel cytokine-directed therapies for asthma. Discov Med.

Novel targeted therapies for eosinophilic disorders.

Reslizumab in children and adolescents with eosinophilic esophagitis: results of a doubleblind, randomized, placebo-controlled trial.

Reslizumab, a humanized monoclonal anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther.

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.

Structure and humanization of a rat monoclonal Fab to human interleukin-5. Protein Eng.

The demise of anti IL-5 for asthma, or not.

Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis.

Garry Walsh

Crossref

http://doaj.org/search?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22term%22%3A%7B%22id%22%3A%229f1517d6c94a4b8e9e05febf8080da4a%22%7D%7D%5D%7D%7D%7D

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

Aberdeen University Research

Crossref